Bayer picks up Teva's animal health biz for $145M

In the second animal health deal announced in two days, generic drug giant Teva Pharmaceutical Industries ($TEVA) says it will sell its animal products line to Bayer of Germany for $145 million so it can concentrate on human drugs.

The deal came a day after up-and-coming generic drugmaker Perrigo ($PRGO) announced that it was buying Sergeant's Pet Care Products, for $285 million.

Terms include $60 million upfront and up to $85 million in milestone payments dependent on the business hitting both manufacturing and sales targets. Bayer gets a portfolio that includes dermatology products sold under the DVM Pharmaceuticals brand, a line of nutraceuticals and a range of food animal products that include anti-infectives, in addition to parasiticides, anti-inflammatories and reproductive hormones such as Prostamate and Ovacyst. In a release, Bayer indicated that it is the food animal franchise that particularly interests it.

The deal includes a plant in St. Joseph, MO, with about 300 employees. Teva says it has been investing heavily in a phased renovation to upgrade its cGMP capabilities.

There is quite a bit of upheaval in the animal health industry these days. In addition to Perrigo getting into the business of selling to pet owners, Pfizer ($PFE) is spinning its animal health division off and, because of production issues, Novartis ($NVS) has been losing market share.

- here's the release

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.